FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2477674016> ?p ?o ?g. }

• W2477674016 abstract "Small fiber neuropathy is the most common cause of neuropathic pain in peripheral neuropathies, with a minimum prevalence of 53/100,000. Patients experience excruciating pain, and currently available anti-neuropathic and other pain drugs do not relieve the pain substantially. Several open-label studies have suggested an immunological basis in small fiber neuropathy and have reported efficacy of treatment with intravenous immunoglobulin. Therefore, immunological mechanisms conceivably may play a role in small fiber neuropathy. To date, no randomized controlled study with intravenous immunoglobulin in patients with small fiber neuropathy has been performed. This study is a randomized, double-blind, placebo-controlled, clinical trial in patients with idiopathic small fiber neuropathy. The primary objective is to investigate the efficacy of intravenous immunoglobulin versus placebo on pain alleviation. A 1-point change in the PI-NRS compared to baseline is considered the minimum clinically important difference. In the IVIg-treated group, we assume a response rate of approximately 60 % based on the criteria composed by the IMMPACT group for measurement of pain. Based on this, a sample size of 60 patients is needed. Eligible patients fulfilling the inclusion/exclusion criteria will be randomized to receive either intravenous immunoglobulin or placebo (0.9 % saline). The treatment regimen will start with a loading dose of 2 g/kg body weight over 2–4 consecutive days, followed by a maintenance dose of 1 g/kg body weight over 1–2 consecutive days given three times at a 3-week interval. The primary endpoint is the comparison of the percentage of responder subjects between the two treatment groups from the first randomization during the 12 weeks of treatment. A responder is defined as ≥ 1-point Pain Intensity Numerical Rating Scale improvement on the mean weekly peak pain relative to baseline. The secondary outcomes are pain intensity, pain qualities, other small fiber neuropathy-related complaints, daily and social functioning, as well as quality of life. In addition, safety assessments will be performed for adverse events, vital signs, and laboratory values outside the normal range. Responders during the 12-week treatment period will be followed during a 3-month extension phase. This is the first randomized, double-blind, placebo-controlled clinical trial with intravenous immunoglobulin in patients with idiopathic small fiber neuropathy. Positive findings will result in a new treatment option for small fiber neuropathy and support an immunological role in this condition. ClinicalTrials.gov, NCT02637700 . Registered on 16 December 2015." @default.
• W2477674016 created "2016-08-23" @default.
• W2477674016 creator A5013956389 @default.
• W2477674016 creator A5015467105 @default.
• W2477674016 creator A5020224380 @default.
• W2477674016 creator A5030805385 @default.
• W2477674016 creator A5054134106 @default.
• W2477674016 date "2016-07-20" @default.
• W2477674016 modified "2023-10-14" @default.
• W2477674016 title "Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial" @default.
• W2477674016 cites W1114907 @default.
• W2477674016 cites W1784797511 @default.
• W2477674016 cites W1850182909 @default.
• W2477674016 cites W1961691594 @default.
• W2477674016 cites W1969856080 @default.
• W2477674016 cites W1980367971 @default.
• W2477674016 cites W1985231384 @default.
• W2477674016 cites W1988509137 @default.
• W2477674016 cites W1991743435 @default.
• W2477674016 cites W2009149764 @default.
• W2477674016 cites W2009366017 @default.
• W2477674016 cites W2018724911 @default.
• W2477674016 cites W2038610115 @default.
• W2477674016 cites W2046868598 @default.
• W2477674016 cites W2049738813 @default.
• W2477674016 cites W2052863031 @default.
• W2477674016 cites W2057996448 @default.
• W2477674016 cites W2062073321 @default.
• W2477674016 cites W2076503095 @default.
• W2477674016 cites W2079112315 @default.
• W2477674016 cites W2079706772 @default.
• W2477674016 cites W2091502308 @default.
• W2477674016 cites W2102471539 @default.
• W2477674016 cites W2103186156 @default.
• W2477674016 cites W2104818454 @default.
• W2477674016 cites W2110330581 @default.
• W2477674016 cites W2112389587 @default.
• W2477674016 cites W2113722160 @default.
• W2477674016 cites W2116748232 @default.
• W2477674016 cites W2117542268 @default.
• W2477674016 cites W2124333964 @default.
• W2477674016 cites W2125313217 @default.
• W2477674016 cites W2127776176 @default.
• W2477674016 cites W2128312888 @default.
• W2477674016 cites W2130070001 @default.
• W2477674016 cites W2131205084 @default.
• W2477674016 cites W2132309748 @default.
• W2477674016 cites W2133693384 @default.
• W2477674016 cites W2159287844 @default.
• W2477674016 cites W2159865397 @default.
• W2477674016 cites W2161344815 @default.
• W2477674016 cites W2167072852 @default.
• W2477674016 cites W2168353850 @default.
• W2477674016 cites W2338837901 @default.
• W2477674016 cites W2425858854 @default.
• W2477674016 cites W4211206901 @default.
• W2477674016 cites W4249116819 @default.
• W2477674016 cites W4361752516 @default.
• W2477674016 doi "https://doi.org/10.1186/s13063-016-1450-x" @default.
• W2477674016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4955261" @default.
• W2477674016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27439408" @default.
• W2477674016 hasPublicationYear "2016" @default.
• W2477674016 type Work @default.
• W2477674016 sameAs 2477674016 @default.
• W2477674016 citedByCount "23" @default.
• W2477674016 countsByYear W24776740162018 @default.
• W2477674016 countsByYear W24776740162019 @default.
• W2477674016 countsByYear W24776740162020 @default.
• W2477674016 countsByYear W24776740162021 @default.
• W2477674016 countsByYear W24776740162022 @default.
• W2477674016 countsByYear W24776740162023 @default.
• W2477674016 crossrefType "journal-article" @default.
• W2477674016 hasAuthorship W2477674016A5013956389 @default.
• W2477674016 hasAuthorship W2477674016A5015467105 @default.
• W2477674016 hasAuthorship W2477674016A5020224380 @default.
• W2477674016 hasAuthorship W2477674016A5030805385 @default.
• W2477674016 hasAuthorship W2477674016A5054134106 @default.
• W2477674016 hasBestOaLocation W24776740161 @default.
• W2477674016 hasConcept C126322002 @default.
• W2477674016 hasConcept C134018914 @default.
• W2477674016 hasConcept C141071460 @default.
• W2477674016 hasConcept C142724271 @default.
• W2477674016 hasConcept C168563851 @default.
• W2477674016 hasConcept C197934379 @default.
• W2477674016 hasConcept C203092338 @default.
• W2477674016 hasConcept C204787440 @default.
• W2477674016 hasConcept C27081682 @default.
• W2477674016 hasConcept C2777107010 @default.
• W2477674016 hasConcept C2779901536 @default.
• W2477674016 hasConcept C2781413609 @default.
• W2477674016 hasConcept C42219234 @default.
• W2477674016 hasConcept C555293320 @default.
• W2477674016 hasConcept C71924100 @default.
• W2477674016 hasConceptScore W2477674016C126322002 @default.
• W2477674016 hasConceptScore W2477674016C134018914 @default.
• W2477674016 hasConceptScore W2477674016C141071460 @default.
• W2477674016 hasConceptScore W2477674016C142724271 @default.
• W2477674016 hasConceptScore W2477674016C168563851 @default.
• W2477674016 hasConceptScore W2477674016C197934379 @default.
• W2477674016 hasConceptScore W2477674016C203092338 @default.

• next